OTC standardized label flexibility, consumer awareness programs supported by NDAC.
This article was originally published in The Rose Sheet
Executive Summary
OTC STANDARDIZED LABEL FLEXIBILITY SUPPORTED BY NDAC members at a Sept. 29 meeting in Rockville, MD. The Nonprescription Drugs Advisory Committee discussed labeling issues at a meeting immediately following an FDA public hearing on OTC drug labeling. After listening to more than five hours of presentations from industry, consumer groups, researchers and other interested parties, NDAC member Eric Brass, MD/PhD, Harbor-UCLA Medical Center, expressed a common opinion when he recommended that FDA "balance the issue of flexibility" as it considers standardizing OTC labels.